FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy
作者： Beatrice Mohelnikova-Duchonova
DOI: 10.3748/WJG.V20.I30.10316
关键词:
摘要: While 5-fluorouracil used as single agent in patients with metastatic colorectal cancer has an objective response rate around 20%, the administration of combinations irinotecan 5-fluorouracil/folinic acid or oxaliplatin results significantly increased rates and improved survival. However, side effects systemic therapy such myelotoxicity, neurotoxicity gastrointestinal toxicity may lead to life-threatening complications have a major impact on quality life patients. Therefore, biomarkers that would be instrumental choice optimal type, combination dose drugs for individual patient are urgently needed. The efficacy anticancer tumor cells is determined by effective concentration cells, healthy tissues presence quantity drug targets. Enzymes active metabolism transport represent important determinants therapeutic outcome. aim this review was summarize published data associations gene protein expression, genetic variability putative 5-fluorouracil/leucovorin/oxaliplatin 5-fluorouracil/leukovorin/irinotecan regimens. Gaps knowledge identified aid design future research clinical trials.
sci-hub.se 参考文章(120)
J. A. Sprowl, G. Ciarimboli, C. S. Lancaster, H. Giovinazzo, A. A. Gibson, G. Du, L. J. Janke, G. Cavaletti, A. F. Shields, A. Sparreboom, Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 110, pp. 11199- 11204 ,(2013) , 10.1073/PNAS.1305321110
Elena De Mattia, Giuseppe Toffoli, Jerry Polesel, Mario D’Andrea, Giuseppe Corona, Vittorina Zagonel, Angela Buonadonna, Eva Dreussi, Erika Cecchin, Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenetics and Genomics. ,vol. 23, pp. 549- 557 ,(2013) , 10.1097/FPC.0B013E328364B6CF
B Glimelius, H Garmo, Å Berglund, L A Fredriksson, M Berglund, H Kohnke, P Byström, H Sørbye, M Wadelius, Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer Pharmacogenomics Journal. ,vol. 11, pp. 61- 71 ,(2011) , 10.1038/TPJ.2010.10
Peter Mu-Hsin Chang, Cheng-Hwai Tzeng, Po-Min Chen, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kae Jiang, Huann-Sheng Wang, Wei-Shu Wang, ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX‐4 treatment in Asian patients with metastatic colorectal carcinoma Cancer Science. ,vol. 100, pp. 278- 283 ,(2009) , 10.1111/J.1349-7006.2008.01031.X
Liu Huang, Tao Zhang, Conghua Xie, Xin Liao, Qianqian Yu, Jueping Feng, Hong Ma, Jing Dai, Min Li, Jigui Chen, Aihua Zang, Qian Wang, Shuwang Ge, Kai Qin, Juan Cai, Xianglin Yuan, SLCO1B1 and SLC19A1 Gene Variants and Irinotecan-Induced Rapid Response and Survival: A Prospective Multicenter Pharmacogenetics Study of Metastatic Colorectal Cancer PLoS ONE. ,vol. 8, pp. e77223- ,(2013) , 10.1371/JOURNAL.PONE.0077223
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein, Pharmacogenomics Knowledge for Personalized Medicine Clinical Pharmacology & Therapeutics. ,vol. 92, pp. 414- 417 ,(2012) , 10.1038/CLPT.2012.96
Kensuke Kumamoto, Keiichiro Ishibashi, Norimichi Okada, Yusuke Tajima, Kouki Kuwabara, Yoichi Kumagai, Hiroyuki Baba, Norihiro Haga, Hideyuki Ishida, None, Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncology Letters. ,vol. 6, pp. 648- 654 ,(2013) , 10.3892/OL.2013.1467
Sarah Park, Chikako Shimizu, Tatsu Shimoyama, Masayuki Takeda, Masashi Ando, Tsutomu Kohno, Noriyuki Katsumata, Yoon-Koo Kang, Kazuto Nishio, Yasuhiro Fujiwara, Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment. ,vol. 99, pp. 9- 17 ,(2006) , 10.1007/S10549-006-9175-2
E Marcuello, D Páez, L Paré, J Salazar, A Sebio, E del Rio, M Baiget, A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. British Journal of Cancer. ,vol. 105, pp. 53- 57 ,(2011) , 10.1038/BJC.2011.206
Beatrice Mohelnikova-Duchonova, Veronika Brynychova, Martin Oliverius, Eva Honsova, Zdenek Kala, Katarina Muckova, Pavel Soucek, Differences in Transcript Levels of ABC Transporters Between Pancreatic Adenocarcinoma and Nonneoplastic Tissues Pancreas. ,vol. 42, pp. 707- 716 ,(2013) , 10.1097/MPA.0B013E318279B861